|1.||Adam, Albert: 5 articles (03/2005 - 01/2002)|
|2.||Lapointe, Nathalie: 5 articles (03/2005 - 01/2002)|
|3.||Rouleau, Jean-Lucien: 4 articles (03/2005 - 01/2002)|
|4.||Rouleau, J L: 4 articles (06/2001 - 08/2000)|
|5.||Packer, Milton: 3 articles (08/2005 - 08/2002)|
|6.||Blais, Charles: 3 articles (12/2003 - 01/2002)|
|7.||Rouleau, Jean L: 3 articles (12/2003 - 05/2002)|
|8.||Clément, Robert: 3 articles (12/2003 - 01/2002)|
|9.||Qian, Chunlin: 3 articles (09/2002 - 06/2002)|
|10.||Jemal, M: 3 articles (12/2001 - 06/2001)|
01/01/2002 - "In patients with heart failure, omapatrilat significantly improved neurohormonal and hemodynamic status. "
03/01/2000 - "The IMPRESS trial of the vasopeptidase inhibitor, omapatrilat, indicated a promising new treatment for the management of heart failure."
09/15/2001 - "Thus, omapatrilat administered orally to patients with heart failure was safe and well tolerated and resulted in improved hemodynamic performance."
08/01/2004 - "We studied a subset of patients enrolled in a randomized trial of omapatrilat for the treatment of heart failure. "
08/20/2002 - "Post hoc analysis of the primary end point with the definition used in the SOLVD Treatment Trial (which included all hospitalizations for heart failure) showed an 11% lower risk in patients treated with omapatrilat (nominal P=0.012). "
|2.||Hypertension (High Blood Pressure)
01/01/2003 - "Omapatrilat: still a promise in salt-sensitive hypertension?"
05/01/2002 - "These actions of omapatrilat may confer protection against end-organ damage characteristic of severe hypertension."
01/01/2004 - "The aim of this study was to determine the cardiorenal effects of the vasopeptidase inhibitor omapatrilat in the transgenic m(Ren-2)27 rat which exhibits fulminant hypertension and severe organ pathology. "
06/25/2002 - "Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study."
05/01/2002 - "Omapatrilat provides long-term control of hypertension: a randomized trial of treatment withdrawal."
02/01/2004 - "Omapatrilat, an agent under development, has been shown to have significantly greater antihypertensive efficacy than existing agents, but may also carry increased risk of angioedema. "
08/01/2003 - "The results of the OCTAVE trial confirmed the antihypertensive efficacy of omapatrilat, but at the price of an angioedema rate more than threefold higher than that of an ACE inhibitor in the overall population (2.17% vs 0.68%), and close to fourfold higher in the black population. "
02/01/2004 - "Two omapatrilat-treated subjects experienced angioedema with airway compromise, which was successfully treated. "
08/01/2003 - "Because angioedema is probably a class side effect of vasopeptidase inhibitors, the higher incidence of this potentially life-threatening complication with omapatrilat has likely stopped the development of this new class of agents. "
11/01/2002 - "The worrying trend was however, that angioedema was more common with Omapatrilat; 24 (0.8%) versus 14 cases (0.5%). "
08/01/2005 - "The OVERTURE echocardiographic study was designed to test the hypothesis that the vasopeptidase inhibitor omapatrilat would attenuate ventricular remodeling and improve ventricular function to a greater extent than an ACE inhibitor. "
02/01/1999 - "In animal models of heart failure, omapatrilat is more effective than ACE inhibition in improving cardiac performance and ventricular remodeling and prolonging survival. "
03/01/2003 - "Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction."
10/01/2001 - "The dual angiotensin I converting enzyme/neutral endopeptidase inhibitor omapatrilat (also called vasopeptidase inhibitor) improves left ventricular remodeling in experimental heart failure. "
04/01/2013 - "Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction."
10/01/2001 - "In conclusion, in addition to being a potent antihypertensive agent, omapatrilat significantly improves cardiac and vascular fibrosis in SHRSP."
05/01/2015 - "However, one such agent (omapatrilat) showed promise of NEP/RAS inhibition in treating CKD in animal models, producing greater reductions in proteinuria, glomerulosclerosis and tubulointerstitial fibrosis compared with isolated RAS inhibition. "
10/01/2001 - "We hypothesized that omapatrilat would induce regression of cardiac and vascular fibrosis in hypertension. "
02/06/2004 - "Myocardial fibrosis was less for omapatrilat than control (P<0.0005) and enalapril (P<0.0005) groups. "
12/01/2003 - "Omapatrilat and captopril resulted in similar improvements of hemodynamic measurements, ventricular weight and dilatation, cardiac fibrosis and myocardial cell cross-section in large MI rats. "
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|6.||Neprilysin (Neutral Endopeptidase)
|10.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Surgical Instruments (Clip)
|3.||Drug Therapy (Chemotherapy)